DARE BIOSCIENCE INC (DARE)

US23666P1012 - Common Stock

0.2801  -0.01 (-5.08%)

Fundamental Rating

1

Overall DARE gets a fundamental rating of 1 out of 10. We evaluated DARE against 198 industry peers in the Pharmaceuticals industry. DARE has a bad profitability rating. Also its financial health evaluation is rather negative. DARE is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

DARE had negative earnings in the past year.
In the past year DARE has reported a negative cash flow from operations.
In the past 5 years DARE always reported negative net income.
DARE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of DARE (-141.70%) is worse than 86.73% of its industry peers.
Industry RankSector Rank
ROA -141.7%
ROE N/A
ROIC N/A
ROA(3y)-93.89%
ROA(5y)-169.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

DARE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

DARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
DARE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, DARE has more shares outstanding
There is no outstanding debt for DARE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -15.43, we must say that DARE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of DARE (-15.43) is worse than 79.59% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -15.43
ROIC/WACCN/A
WACC9.23%

2.3 Liquidity

A Current Ratio of 0.86 indicates that DARE may have some problems paying its short term obligations.
The Current ratio of DARE (0.86) is worse than 90.31% of its industry peers.
A Quick Ratio of 0.86 indicates that DARE may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.86, DARE is doing worse than 84.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.86
Quick Ratio 0.86

More info and screens

4

3. Growth

3.1 Past

DARE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.11%, which is quite good.
DARE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -71.92%.
EPS 1Y (TTM)8.11%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q68.42%
Revenue 1Y (TTM)-71.92%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, DARE will show a very strong growth in Earnings Per Share. The EPS will grow by 44.04% on average per year.
The Revenue is expected to grow by 169.59% on average over the next years. This is a very strong growth
EPS Next Y24.25%
EPS Next 2Y34.91%
EPS Next 3Y31.13%
EPS Next 5Y44.04%
Revenue Next Year236.27%
Revenue Next 2Y301.43%
Revenue Next 3Y212.62%
Revenue Next 5Y169.59%

3.3 Evolution

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DARE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DARE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as DARE's earnings are expected to grow with 31.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.91%
EPS Next 3Y31.13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DARE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DARE BIOSCIENCE INC

NASDAQ:DARE (4/19/2024, 1:38:03 PM)

0.2801

-0.01 (-5.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap27.61M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -141.7%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.86
Quick Ratio 0.86
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)8.11%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y24.25%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-71.92%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y